Abstract HCV infects approximately 2–3% of the global population and is a leading cause of
end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg …

The global spread of hepatitis B virus (HBV) and hepatitis C virus (HCV), their high chronicity
rates and their progression to cirrhosis and hepatocellular carcinoma, are major public …

Combined pegylated interferon (PegIFN) and ribavirin represents the standard therapy for
patients with chronic hepatitis C (CHC), which allows for sustained viral response (SVR) in …

The current standard of care for hepatitis C virus (HCV) infection–combination therapy with
pegylated interferon and ribavirin–elicits sustained responses in only∼ 50% of the patients …

Background Treatment guidelines contraindicate ribavirin for treatment of hepatitis C virus
(HCV) infection in thalassemia major patients. Nevertheless, the current evidence suggests …

Anaemia is a common complication of antiviral therapy for chronic hepatitis C virus (HCV)
infection that necessitates dose reductions or therapy discontinuation. Administration of …

Hepatitis C virus (HCV) infection affects 2–3% of the population, approximately 170 million
people worldwide, causing chronic HCV-related hepatitis with subsequent liver cirrhosis …

OBJECTIVE: To review the literature regarding current strategies for the management of
anemia associated with treatment for chronic viral hepatitis C (HCV) in adults. DATA …

Как улучшить результаты стандартной противовирусной терапии у пациентов с
хроническим гепатитом С: роль кроветворных факторов роста КОРЗИНА ПОИСК …

Background With the development of new direct acting antiviral (DAA) therapy for hepatitis
C, the backbone peginterferon alpha used may be of importance in maximizing treatment …